Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Kite Pharma
NEW YORK, NY / ACCESSWIRE / July 21, 2017 / Both Sarepta Therapeutics and Kite Pharma saw gains on Thursday. Kite hit a new high after highlighting positive results of an anti-CD19 chimeric antigen receptor T-cell therapy study. Shares of Sarepta exploded after the company announced second quarter financial results that beat Wall Street's expectations.
RDI Initiates Coverage on:
Sarepta Therapeutics, Inc.
https://ub.rdinvesting.com/news/?ticker=SRPT
Kite Pharma, Inc.
https://ub.rdinvesting.com/news/?ticker=KITE
Sarepta Therapeutics, Inc. shares closed up 20.10% on Thursday with nearly 20 million shares traded compared to an average volume of roughly 1.4 million. The biotech company announced its second quarter financial results after the bell on Wednesday. Revenue for the period was $35 million, which came in higher than the $22.5 million that analysts had expected. Earnings was a loss of 46 cents per share which was also narrower than the 91 cents per share loss that analysts had called for. The company noted that strong revenue was mainly because of the company's muscular dystrophy drug, Exondys 51. A SunTrust analyst wrote in a note, "We believe Sarepta is on track to become a [Duchenne Muscular Dystrophy]-focused powerhouse." Over the last twelve months, shares of Sarepta are up over 71%.
Access RDI's Sarepta Therapeutics, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=SRPT
Kite Pharma, Inc. shares closed up 4.23% on Thursday and hit a new high of $110.08 during intra-day trading. The cell therapy company saw its shares jump after highlighting recent results in Molecular Therapy from a National Cancer Institute (NCI) study of anti-CD19 chimeric antigen receptor T-cell therapy in patients with aggressive NHL including diffuse large B-cell lymphoma. Chief Medical Officer of the company, David Chang M.D., Ph.D. commented, "We are encouraged to see durable CRs ongoing for more than 3 years, which raises a possibility of cure, from a single infusion of anti-CD19 CAR T cells in patients with chemorefractory DLBCL, a population that previously had no curative treatment options. This study helps us to understand the long-term potential for this anti-CD19 CAR T cell therapy (axicabtagene ciloleucel) in the larger aggressive NHL patient population." Kite is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies that are designed to empower the immune system's ability to recognize and kill tumors.
Access RDI's Kite Pharma, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=KITE
Our Actionable Research on Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Kite Pharma, Inc. (NASDAQ: KITE) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer or a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
